DARVOCET A500 Drug Patent Profile
✉ Email this page to a colleague
When do Darvocet A500 patents expire, and when can generic versions of Darvocet A500 launch?
Darvocet A500 is a drug marketed by Xanodyne Pharm and is included in one NDA.
The generic ingredient in DARVOCET A500 is acetaminophen; propoxyphene napsylate. There are sixty-six drug master file entries for this compound. Additional details are available on the acetaminophen; propoxyphene napsylate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DARVOCET A500?
- What are the global sales for DARVOCET A500?
- What is Average Wholesale Price for DARVOCET A500?
Summary for DARVOCET A500
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 1 |
| Patent Applications: | 8 |
| DailyMed Link: | DARVOCET A500 at DailyMed |
Recent Clinical Trials for DARVOCET A500
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Endo Pharmaceuticals | Phase 4 |
| University of Rochester | Phase 4 |
US Patents and Regulatory Information for DARVOCET A500
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xanodyne Pharm | DARVOCET A500 | acetaminophen; propoxyphene napsylate | TABLET;ORAL | 076429-001 | Sep 10, 2003 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
